Dare Bioscience Inc

0.00 (0.00%)
: $1.00 -0.02 (-2.16%)
Products, Regulatory

Dare Bioscience Announces Positive Topline Results From Phase 3 Trial Of DARE-BV1 In Patients With Bacterial Vaginosis

Published: 12/07/2020 13:08 GMT
Dare Bioscience Inc (DARE) - DarÉ Bioscience Announces Positive Topline Results From Dare-bvfree, a Phase 3 Trial of Dare-bv1 in Patients Diagnosed With Bacterial Vaginosis.
Dare Bioscience Inc - New Drug Application (nda) Submission Planned 1h of 2021 for Dare-bv1.
Dare Bioscience Inc - Dare-bv1 Met Primary Endpoint of Study and All Pre-specified Secondary Efficacy Endpoints.
Dare Bioscience Inc - Dare-bv1 Demonstrated Significantly Greater Clinical Cure Rates Compared to Placebo.
Dare Bioscience - NDA for Dare-bv1, If Granted, Could Allow for 2021 PDUFA Date, And, Assuming Approval, an Early 2022 Commercial Launch in U.S.